See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Donald Trump
Baseball
Vladimir Putin
Israel-Hamas Conflict
Ukraine War
Elon Musk
Premier League
Hamas
Immigration
Social Media
Published • loading... • Updated

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Summary by Benzinga
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant  Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma  Second approval in…

4 Articles

All
Left
Center
1
Right
BenzingaBenzinga
Reposted by
ADKhabarADKhabar

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant  Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma  Second approval in…

·New York, United States
Read Full Article
onclive.comonclive.com

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

Read Full Article
pharmafile.compharmafile.com

MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients - Pharmafile

The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma in patients who are ineligible for a transplant from Sanofi. The decision comes just days after approval from the European Commission. Influenced by the results of the IMROZ study, isatuximab is now licensed in the […] The post MHRA approve new treatment combo for transplant-ineligible mult…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmafile.com broke the news in on Thursday, January 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

China

China

News
For You
Search
BlindspotLocal